PYPD News and Press, PolyPid Ltd. From 04/29/21

PETAH TIKVA, Israel, April 29, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will report its first quarter 20...

The following slide deck was published by PolyPid Ltd. in conjunction with this event. For further details see: PolyPid (PYPD) Investor Presentation - Slideshow

PETAH TIKVA, Israel, Feb. 23, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will present at the Raymo...

Top-line Data Anticipated by Year End 2021 Enrollment Also Continues to Progress in Company’s Second Phase 3 Clinical Trial , SHIELD I I PETAH TIKVA, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-st...

PolyPid Ltd. (PYPD) Q4 2020 Earnings Conference Call February 10, 2021 8:30 AM ET Company Participants Bob Yedid – Managing Director-LifeSci Advisors Dikla Czaczkes Akselbrad – Executive Vice President and Chief Financial Officer Noam Emanuel – Founder and Chief Scientifi...

PolyPid (PYPD): Q4 GAAP EPS of -$0.41.As of December 31, 2020, the Company had cash and cash equivalents, short-term deposits and long-term deposits in the amount of $66.6 million, compared to $26.6 million at December 31, 2019.Press Release For further details see: PolyPid re...

100 Patient s Enrolled into Phase 3 SHIELD I and SHIELD II Trial s of D-PLEX 100 in Abdominal Surgery Recently Initiated Phase 3 SHIELD II Trial Granted Breakthrough Therapy Designation from FDA for D-PLEX 100 ...

PETAH TIKVA, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announce...

PolyPid ([[PYPD]] +9.9%) has reported preclinical data from its OncoPLEX intra-tumoral cancer therapy program, demonstrating single local treatment showed improved overall survival and significantly less tumor recurrence when compared to multiple injections with standard systemic Chemoth...

Single Local Treatment of OncoPLEX Showed Improved Overall Survival and Significantly Less Tumor Recurrence, and Reduced Systemic Toxicity Compared to Multiple Injections with Standard Systemic Chemotherapy in a Syngeneic Mouse Model for Solid Tumors of Colon Carcinoma Compa...